Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorSahlgrenska University Hospital

About this trial

The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is:

Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A/B (maximum 2 nodes, <30 mm in any dimension)

Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, <30 mm in any dimension)

Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)

Disqualifiers

Previous chemotherapy (including adjuvant chemotherapy at diagnosis)

Previous RPLND

Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires

Trial design

Design model

Parallel

Treatments tested in this trial

  • primary RPLND for low-stage metasatatic seminoma

    Procedure/Surgery

    surgical lymph node dissection

  • 3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP)

    Drug

    systemic tretament for good prognosis metastastic testicular cancer

Treatment groups

160 Participants
are divided into 2 treatment groups
Group A: Surgery groupActive comparator 1 intervention
Group B: Chemotherapy groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

HRQOL after treatment as measured by the EORTC QLQ-C30 with the testicular cancer-specific supplement EORTC QLQ-TC26

Changes across study-groups in global HRQOL after treatment as measured by the EORTC QLQ-C30 with the testicular cancer-specific supplement EORTC QLQ-TC26 The QLQ-C30 comprises both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

Time frame
2 years

Secondary outcomes

1

Fatigue after RPLND vs. chemotherapy

Differences in fatigue across study-groups as measured by the Fatigue Questionnaire (FQ). The FQ is an established, self-report fatigue questionnaire comprising 14 items that assess the intensity of fatigue-related symptoms. Each item was rated on a 4-point Likert scale (0 'better than usual', 1 'no more than usual', 2 'worse than usual', 3 'much worse than usual'). The FQ score is the sum of all items' scores (range 0-42).

Time frame
2 years
2

Ejaculation problems

Differences across study-groups in patient-reported prevalence of retrograde ejaculation as assessed by two "supplementary" questions. These questions concern difficulties achieving ejaculation following sexual stimulation and whether the amount of semen is considered a problem. Answers are given on 4-point scales (no sexual stimulation has occurred, big difficulties (achieving ejaculation), small difficulties, no difficulties, and no sexual stimulation has occurred, large problem (amount of semen), small problem, no problem, respectively).

Time frame
2 years
3

Treatment related complications

Rate of doctor-reported complications related to treatment in the study-groups. Journals are reviewed to gather information regarding the time and type of complication. Surgery group: Surgical complications are classified according to the Clavien-Dindo (CD) system, a standardised, 5-grade system used to grade surgical complications based on the level of therapeutic intervention required to manage them. Chemotherapy group: Complications following chemotherapy are classified according to the Common Terminology Criteria for Adverse Events, using a 1-5 scale to grade the severity of the event.

Time frame
2 years
4

Healt economy

Differences in quality-adjusted life years across study groups as measured by the EQ-5D-5L tool, consisting of an index varying from 1 (full health) to 0 (dead), with scores below 0 indicating states worse than being dead. The index is evaluated at baseline (before start of treatment) and at 3, 6, 12 and 24 months thereafter.

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sahlgrenska University Hospital

Lead sponsor

Karolinska University Hospital

Collaborator

Haukeland University Hospital

Collaborator

University Hospital of North Norway

Collaborator

Oslo University Hospital

Collaborator

Trondheim University Hospital

Collaborator

Uppsala University Hospital

Collaborator

University Hospital, Umeå

Collaborator

Lund University Hospital

Collaborator